Furthermore, the combined inhibition of JAK2 and ERK1/2 with ruxolitinib and ERK inhibitors, respectively, reduces the proliferation of Jak2 V617F cells, normalizes erythrocytosis and corrects the splenomegaly of Jak2 V617F MPN mice [153]. This evidence concerns the gene MAPK3 and myeloproliferative neoplasm.